

PTO-1449, REPRODUCED		ATTORNEY DOCKET NO. 0975.1005-012		APPLICATION NO. 09/897,724	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION October 9, 2002 (attach several sheets if necessary)				APPLICANT Junming Le et al.	
FILING DATE July 2, 2001				GROUP 1642	
U.S. PATENT DOCUMENTS					
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	FILED DATE IF APPROPRIATE
KAC	AE2	4,816,567	03/28/89	Cabilly et al.	
	AF2	5,075,236	12/24/91	Yone et al.	
	AG2	5,959,087	09/28/99	Rathjen et al.	
	AH2	5,360,716	11/01/94	Ohmoto, Y. et al.	
FOREIGN PATENT DOCUMENTS					
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	TRANSLATION YES NO
KAC	AQ5	WO92/01059	23 JAN 92	PCT	
	AL7	02-227095	10 SEP 90	JP	X
	AM7	61-047500	07 MAR 86	JP	X
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
KAC	AT11	Yan, L. et al., "Preparation and Characterization of Monoclonal Antibodies Against Recombinant Human Tumor Necrosis Factor Alpha", <i>Chinese J. Biotechnology</i> , 7(2):121-126 (1991).			
	AU11	Mateo, C. et al., "Removal of Amphipathic Epitopes from Genetically Engineered Antibodies: Production of Modified Immunoglobulins with Reduced Immunogenicity", <i>Hybridoma</i> , 19(6):463-471 (2000).			
	AV11	Paul, W.E. (Ed.), <i>Fundamental Immunology</i> , 3 rd Edition, Pub. Raven Press Ltd., pp. 292-293 (1993).			
	AW11	Borrebaeck, C.A.K. (Ed.), <i>Antibody Engineering</i> , 2 nd Edition, Pub. Oxford University Press, p. 291 (1995).			
	AX11	Socher, S. et al., "Antibodies against amino acids 1-15 of tumor necrosis factor block its binding to cell-surface receptor", <i>Proc. Natl. Acad. Sci., USA</i> 84:8829-8833 (1987).			
	AY11	Goh, C., "Tumour Necrosis Factors in Clinical Practice", <i>Annals of the Academy of Medicine</i> , 19(2):235-239 (1990).			
EXAMINER		DATE CONSIDERED			
J. A. Gamble		6/21/2004			

RECEIVED

OCT 16 2002

TECH CENTER 1600/290

[X] Applicant requests that the following pending applications be considered:

Examiner's
Initials

X

U.S. Patent Application No. 10/227,488, by Junming Le, Jan Vilcek, Peter Daddona,
John Ghrayeb, David M. Knight and Scott Siegel, filed August 23, 2002, Docket No.:
0975.1005-025

RECEIVED

OCT 16 2002

Harold G. Gamble
Examiner

6/21/2004
Date

TECH CENTER 1600/2900

- [X] The specification for the above cited co-pending application is identical to the present specification (09/897,724). Therefore, only a copy of the current claims for this application is enclosed. Copies of the specifications of the co-pending application will be provided upon request.
- [] A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

- [] A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.
- [] Please charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is enclosed.
- [X] Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Deirdre E. Sanders
Deirdre E. Sanders
Registration No.: 42,122
Telephone: (978) 341-0036
Facsimile: (978) 341-0136

Concord, Massachusetts 01742-9133

Dated: October 9, 2002

PTO:1449 REPRODUCED

ATTORNEY DOCKET NO.
0975.1005-012

APPLICATION NO.
09/897,724

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

APPLICANT
Junming Le et al.

SEP 16 2002
September 13, 2002

FILING DATE
July 2, 2001

GROUP
1642

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
KAL	AA	4,603,106	07/29/86	Cerami et al.			
	AB	4,822,776	04/18/89	Cerami et al.			
	AC	5,658,570	08/19/97	Newman et al.			
	AD	5,750,105	5/12/98	Newman et al.			
	AE	5,231,024	7/27/93	Moeller et al.			
	AF	5,223,395	06/29/93	Gero			
	AG	5,436,154	07/25/95	Barbanti et al.			
	AH	5,654,407	08/05/97	Boyle et al.			
	AI	5,700,788	12/23/97	Mongelli et al.			
	AJ	5,730,975	03/24/98	Hotamisligil et al.			
	AK	5,741,488	04/21/98	Feldman et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
KAL	AL	0 212 489 B1	04 MAR 87	EPO			
	AM	0 218 868 A2	22 APR 87	EPO			
	AN	0 308 378 B1	22 MAR 89	EPO			
	AO	0 380 068 A1	01 AUG 90	EPO			
	AP	0 393 438 A2	24 OCT 90	EPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)



KAL	AR	Beutler, B. et al., "Identity of tumour necrosis factor and the macrophage-secreted factor cachectin," <i>Nature</i> , 316:552-554 (1985).
	AS	Beutler, B. et al., "Passive Immunization Against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin," <i>Science</i> , 229:869-871 (1985).
	AT	Morrison, Sherie L., "Transfectomas Provide Novel Chimeric Antibodies," <i>Science</i> , 229:1202-1207 (1985).

EXAMINER

Karen P. Gavella

DATE CONSIDERED

6/26/2004



PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.
0975.1005-012APPLICATION NO.
09/897,784INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

September 13, 2002

(Use several sheets if necessary)

APPLICANT
Junming Le et al.FILING DATE
July 2, 2001GROUP
1642

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
KAL	AA2	5,776,947	07/07/98	Kroemer et al.			
	AB2	6,015,558	01/18/00	Hotamisligil et al.			
	AC2	6,172,202 B1	01/09/01	Marcucci et al.			
	AD2	6,194,451 B1	02/27/01	Alpegiani et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
KAL	AQ	0 398 327 B1	22 NOV 90	EPO			
	AL2	0 412 486 B1	13 FEB 91	EPO			
	AM2	0 433 900 B1	26 JUN 91	EPO			
	AN2	0 526 905 A2	10 FEB 93	EPO			
	AO2	WO91/02078	21 FEB 91	PCT			
	AP2	WO92/07076	30 APR 92	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

KAL	AU	Liang, Chi-Ming et al., "Production and Characterization of Monoclonal Antibodies Against Recombinant Human Tumor Necrosis Factor/Cachectin," Biochem. & Biophys. Res. Comm., 137(2):847-854 (1986).
	AV	Hirai, Makoto et al., "Production and characterization of monoclonal antibodies to human tumor necrosis factor," J. of Immun. Methods, 96:57-62 (1987).
	AW	Piguet, Pierre-Francois et al., "Tumor Necrosis Factor/Cachectin is an Effector of Skin and Gut Lesions of the Acute Phase of Graft-vs.-Host Disease," J. Exp. Med., 166:1280-1289 (1987).
	AX	Meager, Anthony et al., "Preparation and Characterization of Monoclonal Antibodies Directed Against Antigenic Determinants of Recombinant Human Tumour Necrosis Factor (rTNF)," Hybridoma, 6(3):305-311 (1987).
	AY	Fendly, Brian M. et al., "Murine Monoclonal Antibodies Defining Neutralizing Epitopes on Tumor Necrosis Factor," Hybridoma, 6(4):359-370 (1987).

EXAMINER

DATE CONSIDERED

Karin A. Gendler

6/21/2004

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.
0975.1005-012APPLICATION NO.
09/897-224INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

September 13, 2002

APPLICANT
Junming Le et al.FILING DATE
July 2, 2001GROUP
1642

(See several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
KAC	AQ2 WO 92/13095	06 AUG 92	PCT			
	AL3 0 260 610 B1	23 MAR 88	EPO			
	AM3 91/09967	11 JUL 91	PCT			
	AN3 0 351 789 B1	24 JAN 90	EPO			
	AO3 0 350 690 A2	17 JAN 90	EPO			
	AP3 90/00902	08 FEB 90	PCT			
	AQ3 WO 92/11383	09 JUL 92	PCT			
	AL4 WO 93/02108	04 FEB 93	PCT			
	AM4 WO 92/16553	19 MAR 92	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)



KAC	AZ	Bringman, Timothy S. and Aggarwal, Bharat B., "Monoclonal Antibodies to Human Tumor Necrosis Factors Alpha and Beta: Applications for Affinity Purification, Immunoassays, and as Structural Probes," <i>Hybridoma</i> , 6(5):489-507 (1987).
	AR2	Tracey, Kevin J. et al., "Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia," <i>Nature</i> , 330:662-664 (1987).
	AS2	Nagai, M. et al., "Antibody to tumor necrosis factor (TNF) reduces endotoxin fever," <i>Experientia</i> , 44:606-607 (1988).
	AT2	Shimamoto, Yoshinori et al., "Monoclonal antibodies against human recombinant tumor necrosis factor: prevention of endotoxic shock," <i>Immunology Letters</i> , 17:311-318 (1988).
	AU2	Di Giovine, Francesco, S. et al., "Tumour necrosis factor in synovial exudates," <i>Annals of the Rheumatic Diseases</i> , 47:768-772 (1988).
	AV2	Collins, M.S. et al., "Immunoprophylaxis of Polymicrobial Cellulitis with a Human Monoclonal Antibody Against Lipopolysaccharide Antigen of <i>Pseudomonas aeruginosa</i> ," Abstract E-63, Abstracts of Annual Meeting 1989.

EXAMINER


DATE CONSIDERED

Karen Q. Gaudin

4/21/2004



PTO-1449 REPRODUCED



INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

SEP 16 2002

September 13, 2002

(Use several sheets if necessary)

ATTORNEY DOCKET NO.
0975.1005-012

APPLICATION NO.
09/897,728

APPLICANT
Junming Le et al.

FILING DATE
July 2, 2001

GROUP
1642

RECEIVED
SEP 17 2002
FBI CENTER 160012900

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
KAC	AN4 WO 91/09967	11 JUL 91	PCT			
	AO4 0 486 526 B2	07 MAR 01	EPO			
	AP4 PCT/US92/02190	10 JUN 92	PCT			
	AQ4 0 288 088 B1	26 OCT 88	EPO			
	AL5 0 453 898 A2	30 OCT 91	EPO			X
	AM5 0 585 705 A1	09 MAR 94	EPO			
	AN5 0 614 984 A2	14 SEP 94	EPO			
	AO5 0 663 836 B1	26 JUL 95	EPO			
	AP5 WO 89/08460	21 SEP 89	PCT			
	AQ5 WO 90/01950	08 MAR 90	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

KAC	AM2	Exley, A.R. et al., "Monoclonal Antibody (Mab) to Recombinant Human Tumour Necrosis Factor (rhTNF) in the Prophylaxis and Treatment of Endotoxic Shock in Cynomolgus Monkeys," Medical Research Society, Abstract 184, p. 50 (1989).
	AX2	Cross, A.S. et al., "Pretreatment with Recombinant Murine Tumor Necrosis Factor α /Cachectin and Murine Interleukin 1 α Protects Mice from Lethal Bacterial Infection," J of Exp Med., 169:2021-2027 (1989).
	AX2	Engelmann, Hartmut et al., "A Tumor Necrosis Factor-binding Protein Purified to Homogeneity from Human Urine Protects Cells from Tumor Necrosis Factor Toxicity," J. of Bio. Chem., 264(20):11974-11980 (1989).

EXAMINER

Kevin Q. Gault

DATE CONSIDERED

6/21/2004

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.

0975.1005-012

APPLICATION NO.

09/897,725

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

SEP 16 2002

September 13, 2002

(Use several sheets if necessary)

APPLICANT

Junming Le et al.

FILING DATE

July 2, 2001

GROUP

1642

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
KK	AL6 WO 91/04054	04 APR 91	PCT			
	AM6 WO 92/01472	06 FEB 92	PCT			
	AN6 WO 93/11236	10 JUN 93	PCT			
	AO6 WO 94/08609	28 APR 94	PCT			
	AP6 WO 94/08619	28 APR 94	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AZ2	Kawasaki, Hajime et al., "Analysis of Endotoxin Fever in Rabbits by Using a Monoclonal Antibody to Tumor Necrosis Factor (Cachectin)," <i>Infection and Immunity</i> , 57(10):3131-3135 (1989).
AR3	Fong, Yuman et al., "Antibodies to Cachectin/Tumor Necrosis Factor Reduce Interleukin 1 β and Interleukin 6 Appearance During Lethal Bacteremia," <i>J. Exp. Med.</i> , 170:1627-1633 (1989).
AS3	Von Asmuth, E.J.U. et al., "Tumour Necrosis Factor Alpha (TNF- α) and Interleukin 6 in a Zymosan-Induced Shock Model," <i>Scand. J. Immunol.</i> , 32:313-319 (1990).
AT3	Herve, P. et al., "Monoclonal Anti TNF α Antibody for the Treatment of Severe Acute GvHD in Humans," Abstract 3.25, <i>Lymphoma Res.</i> 9:591 (1990).
AU3	Silva, Ayona T. et al., "Prophylactic and Therapeutic Effects of a Monoclonal Antibody to Tumor Necrosis Factor- α in Experimental Gram-Negative Shock," <i>J. of Infectious Diseases</i> , 162:421-427 (1990).
AV3	Opal, Steven M. et al., "Efficacy of a Monoclonal Antibody Directed Against Tumor Necrosis Factor in Protecting Neutropenic Rats from Lethal Infection with <i>Pseudomonas aeruginosa</i> ," <i>J. of Infectious Diseases</i> , 161:1148-1152 (1990).
AW3	Tavernier, Jan et al., "Analysis of the Structure-Function Relationship of Tumour Necrosis Factor. Human/Mouse Chimeric TNF Proteins: General Properties and Epitope Analysis," <i>J. Mol. Biol.</i> , 211:493-501 (1990).
AX3	Lucas, R. et al., "Generation and characterization of a neutralizing rat anti-rm TNF- α monoclonal antibody," <i>Immunology</i> , 71:218-223 (1990).

EXAMINER

Karen J. Gamble

DATE CONSIDERED

6/21/2004

RECEIVED
SEP 17 2002
FBI CENTER 1600/2900

PTO-1449 REPRODUCED

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

SEP 16 2002

September 13, 2002

(Use several sheets if necessary)

ATTORNEY DOCKET NO.
0975.1005-012

APPLICATION NO.
09/897,724

APPLICANT
Junming Le et al.

FILING DATE
July 2, 2001

GROUP
1642

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AY3	KAC	Hinshaw, L.B. et al., "Survival of Primates in LD ₁₀₀ Septic Shock Following Therapy with Antibody to Tumor Necrosis Factor (TNF α)," <i>Circulatory Shock</i> , 30:279-292 (1990).
A23		Nophar, Yaron et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type 1 TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor," <i>The EMBO Journal</i> , 9(10):3269-3278 (1990).
AB4		Engelmann, Hartmut et al., "Two Tumor Necrosis Factor-binding Proteins Purified from Human Urine," <i>J. of Bio. Chem.</i> , 265(3):1531-1536 (1990).
AB4		Verhoef, J. and Torensma, R., "Prospects for Monoclonal Antibodies in the Diagnosis and Treatment of Bacterial Infections," <i>Eur. J. Clin. Microbiol. Dis.</i> , 9(4):247-250 (1990).
AT4		Loetscher, Hansruedi et al., "Molecular Cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor," <i>Cell</i> , 61:351-359 (1990).
AI4		Schall, Thomas J. et al., "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor," <i>Cell</i> , 61:361-370 (1990).
AV4		Akama, Hideto et al., "Mononuclear Cells Enhance Prostaglandin E ₂ Production of Polymorphonuclear Leukocytes via Tumor Necrosis Factor α ," <i>Biochemical and Biophysical Research Comm.</i> , 168(2):857-862 (1990).
AW4		Exley, A.R. et al., "Monoclonal antibody to TNF in severe septic shock," <i>The Lancet</i> , 335:1275-1277 (1990).
AX4		Möller, Achim et al., "Monoclonal Antibodies to Human Tumor Necrosis Factor α : In Vitro and In Vivo Application," <i>Cytokine</i> , 2(3):162-169 (1990).
AY4		Ruddle, Nancy H. et al., "An Antibody to Lymphotoxin and Tumor Necrosis Factor Prevents Transfer of Experimental Allergic Encephalomyelitis," <i>J. Exp. Med.</i> , 172:1193-1200 (1990).

EXAMINER

Karen A. Gendle

DATE CONSIDERED

6/21/2004

RECEIVED
SEP 17 2002
TECH CENTER 18012900

PTO-1000 REPRODUCED INFORMATION DISCLOSURE CITATION ON AN APPLICATION September 13, 2002 (Several sheets if necessary)		ATTORNEY DOCKET NO. 0975.1005-012	APPLICATION NO. 09/897,724
		APPLICANT Junming Le et al.	
		FILING DATE July 2, 2001	GROUP 1642
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
<input checked="" type="checkbox"/>	AZ4	Galloway, Cynthia J. et al., "Monoclonal anti-tumor necrosis factor (TNF) antibodies protect mouse and human cells from TNF cytotoxicity," <i>J. of Immunological Methods</i> , 140:37-43 (1991).	
<input checked="" type="checkbox"/>	AR5	Waldmann, Thomas A., "Monoclonal Antibodies in Diagnosis and Therapy," <i>Science</i> , 252:1657-1662 (1991).	
<input checked="" type="checkbox"/>	AS5	Aderka, Dan et al., "The Possible Role of Tumor Necrosis Factor (TNF) and Its Natural Inhibitors, The Soluble-TNF Receptors, In Autoimmune Diseases," <i>Israel J. Med. Sci.</i> , 28(2):126-130 (1992).	
<input checked="" type="checkbox"/>	AS5	Pennington, James, "TNF: Therapeutic Target in Patients with Sepsis," <i>ASM News</i> , 58(9):479-482 (1992).	
<input checked="" type="checkbox"/>	AS5	Harris, William J. and Emery, Steven, "Therapeutic antibodies - the coming of age," <i>TBTECH</i> , 11:42-44 (1993).	
<input checked="" type="checkbox"/>	AV5	Parrillo, Joseph E., "Pathogenetic Mechanisms of Septic Shock," <i>N.E. Journal of Medicine</i> , 328(20):1471-1477 (1993).	
<input checked="" type="checkbox"/>	AW5	Aggarwal, Bharat B. et al., "Human Tumor Necrosis Factor Production, Purification and Characterization," <i>J. of Biol. Chem.</i> , 260(4):2345-2354 (1985).	
<input checked="" type="checkbox"/>	AX5	Beutler, B. et al., "Purification of Cachectin, A Lipoprotein Lipase-Suppressing Hormone Secreted by Endotoxin-induced RAW 264.7 Cells," <i>J. Exp. Med.</i> , 161:984-995 (1985).	
<input checked="" type="checkbox"/>	AY5	Echtenacher, Bernd et al., "Requirement of Endogenous Tumor Necrosis Factor/Cachectin for Recovery from Experimental Peritonitis," <i>J. of Immunology</i> , 145(11):3762-3766 (1990).	
<input checked="" type="checkbox"/>	AZ5	Smith, Craig R., "Human and Chimeric Antibodies to LPS and TNF," 4Abstract, <i>Endotoxemia & Sepsis Conference</i> (1991).	
<input checked="" type="checkbox"/>	AR6	Bodmer, Mark, "Humanized Antibodies for Anti-TNF Therapy," Abstract, <i>Endotoxemia & Sepsis Conference</i> (1991).	
<input checked="" type="checkbox"/>	AR6	Genebank Accession, No. N90300 (1989, November 1).	
<input checked="" type="checkbox"/>	AT6	Genebank Accession, No. M32046 (1990, June 15).	
<input checked="" type="checkbox"/>	AU6	Paulus, H., "Preparation and Biomedical Applications of Bispecific Antibodies," <i>Behring Inst. Mitt</i> , No.78:118-132 (1985).	
<input checked="" type="checkbox"/>	AV6	Whittle, Nigel, et al., "Construction and Expression of a CDR-Grafted Anti-TNF Antibody," <i>J. Cell Biochem, Supl.</i> 13A:96 (1989).	
<input checked="" type="checkbox"/>	AW6	Gorman, S.D. and Clark, M.R., "Humanisation of monoclonal antibodies for therapy," <i>Sem Immunol</i> , 2:457-466 (1990).	
<input checked="" type="checkbox"/>	AX6	Starnes, H. Fletcher, Jr., et al., "ANTI-IL-6 Monoclonal Antibodies Protect Against Lethal <i>Escherichia Coli</i> Infection and Lethal Tumor Necrosis Factor Challenge in Mice," <i>J Immunol</i> , 145:4185-4191 (1990).	
EXAMINER <i>Norm G. Gammella</i>		DATE CONSIDERED 6/21/2004	

 RECEIVED
 SEP 17 2002
 TECH CENTER 160012900

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 0975.1005-012	APPLICATION NO. 09/897324
INFORMATION DISCLOSURE CITATION IN AN APPLICATION SEP 16 2002 September 13, 2002		APPLICANT Junming Le et al.	
Use several sheets if necessary		FILING DATE July 2, 2001	GROUP 1642

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AY6	Duncombe, Andrew S. et al., "Tumor Necrosis Factor Mediates Autocrine Growth Inhibition in a Chronic Leukemia," <i>J Immunol</i> , 143:3828-3834 (1989).
A26	Aderka, Dan et al., "IL-6 Inhibits Lipopolysaccharide-Induced tumor Necrosis Factor Production in Cultured Human Monocytes, U937 Cells, and in Mice," <i>J Immunol</i> , 143:3517-3523 (1989).
AN7	Aderka, Dan, "Role of Tumor Necrosis Factor in the Pathogenesis of Intravascular Coagulopathy of Sepsis: Potential New Therapeutic Implications," <i>Isr J Med Sci</i> , 27:52-60 (1991).
AS7	Lassalle, Ph., et al., "Potential Implication of Endothelial Cells in Bronchial Asthma," <i>Int Arch Allergy Appl Immunol</i> , 94:233-238 (1991).
AT7	Fong, Yuman and Lowry, Stephen F., "Tumor Necrosis Factor in the Pathophysiology of Infection and Sepsis," <i>Clin Immunol Immunopathol</i> , 55:157-170 (1990).
AU7	Eck, Michael J. and Sprang, Stephen R., "The Structure of Tumor Necrosis Factor- α at 2.6 Å Resolution," <i>J Biol Chem</i> , 264:17595-17605 (1989).
AV7	Gillies, Stephen D. et al., "High-level expression of chimeric antibodies using adapted cDNA variable region cassettes," <i>J Immunol Methods</i> , 125:191-202 (1989).
AW7	Kameyama, Koh-zoh, et al., "Convenient plasmid vectors for construction of chimeric mouse/human antibodies," <i>FEBS Lett</i> , 244:301-306 (1989).
AX7	Hayashi, H. et al., "An Enzyme-linked Immunosorbent Assay for Recombinant Human Tumor Necrosis Factor Using Monoclonal Antibody," <i>Recent Adv. Chemother</i> , 820-821 (1985).
AY7	Hirai, Makoto et al., "Production and characterization of monoclonal antibodies to human tumor necrosis factor," <i>J Immunol Methods</i> , 96:57-62 (1987).
AS7	Sunahara, N. et al., "Simple enzyme immunoassay methods for recombinant human tumor necrosis factor α and its antibodies using a bacterial cell wall carrier," <i>J Immunol Methods</i> , 109:203-214 (1988).
AR8	Oliff, A., et al., "Tumors Secreting Human TNF/Cachectin Induce Cachexia in Mice," <i>Cell</i> , 50:555-563 (1987).
AS8	Mule, J.J., et al., "Antitumor Activity of Recombinant Interleukin 6 in Mice," <i>The Journal of Experimental Medicine</i> , 171:629-636 (1990).
AT8	Luettig, B., et al., "Evidence For The Existence Of Two Forms Of Membrane Tumor Necrosis Factor: An Integral Protein And A Molecule Attached To Its Receptor," <i>The Journal of Immunology</i> , 143:4034-4038 (1989).
EXAMINER	DATE CONSIDERED
Garen A. Gamella	6/21/2004

Sheet 1 of 10

PTO-1449 REPRODUCED OIP INFORMATION DISCLOSURE CITATION AN APPLICATION SEP 16 2002 September 13, 2002 (Several sheets if necessary)	ATTORNEY DOCKET NO. 0975.1005-012	APPLICATION NO. 09/897,724
	APPLICANT Junming Le et al.	
	FILING DATE July 2, 2001	GROUP 1642

RECEIVED
TECH CENTER 1800/2900
SEP 17 2002

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AX8	AU8	Barbuto, J.A.M., et al "Production of neutralizing antibodies to tumor necrosis factor by human tumor-infiltrating B lymphocytes," <i>Proceedings of the American Association for Cancer Research</i> , 34:487, Abstract 2904, (1993).
AX8	AV8	Bendtzen, K., et al., "Auto-Antibodies To IL-1 α and TNF α In Normal Individuals And In Infectious And Immunoinflammatory Disorders," <i>The Physiological and Pathological Effects of Cytokines</i> , 10B:447-452 (1990).
AX8	AW8	Pomsgaard, A., et al., "Auto-Antibodies To Tumour Necrosis Factor α In Healthy Humans And Patients With Inflammatory Diseases And Gram-Negative Bacterial Infections," <i>Scand. J. Immunol.</i> , 30:219-223 (1989).
AX8	AX8	James, K. and Bell, G.T., "Human Monoclonal Antibody Production Current Status And Future Prospects," <i>Journal of Immunological Methods</i> , 100:5-40 (1987).
AY8	AY8	Alberts, B. et al., <i>Molecular Biology of the Cell</i> , Garland Publishing Inc., pp.182-183 (1983).
AX8	AX8	Simpson, S.Q., et al., "Role Of Tumor Necrosis Factor In Sepsis And Acute Lung Injury," <i>Critical Care Clinics</i> , 5:27-47 (1989).
AX9	AX9	Bendtzen, K., et al., "Native inhibitors (autoantibodies) of IL-1 α and TNF," <i>Immunology Today</i> , 10(7):222 (1989).
AS9	AS9	Davenport, C., et al., "Stimulation Of Human B Cells Specific For Candida Albicans For Monoclonal Antibody Production," <i>FEMS Microbiol Immunol</i> , 4(6):335-343 Abstract (1992).
AT9	AT9	Pennica, D., et al., "Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin," <i>Nature</i> , 312(20/27):724-729 (1984).
AU9	AU9	Gray, P.W., et al., "Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity," <i>Nature</i> , 312(20/27):721-724 (1984).
AV9	AV9	Petersen, C.M., et al., "Bioactive human recombinant tumor necrosis factor- α : an unstable dimer?," <i>Eur. J. Immunol.</i> , 19:1887-1894 (1989).
AW9	AW9	Smith, C. A., et al., "A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins," <i>Science</i> , 248:1019-1023 (1990).
AX9	AX9	Brennan, F.M., et al., "Inhibitory Effect Of TNF α Antibodies On Synovial Cell Interleukin-1 Production In Rheumatoid Arthritis," <i>The Lancet</i> , 244-247 (1989).
AY9	AY9	Hahn, T., et al., "Use of monoclonal antibodies to a human cytotoxin for its isolation and for examining the self-induction of resistance to this protein," <i>Proc. Natl. Acad. Sci. USA</i> 82:3814-3818 (1985).
EXAMINER <i>Harun A. Gennella</i>		DATE CONSIDERED 6/21/2004

PTO. 1-110 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION SEP 16 2002 SEPTEMBER 13, 2002 Several sheets if necessary)	ATTORNEY DOCKET NO. 0975.1005-012	APPLICATION NO. 09/897,724
	APPLICANT Junming Le et al.	
	FILING DATE July 2, 2001	GROUP 1642
	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	

KAZ	AZ9	Grau, G.E., et al., "Tumor Necrosis Factor (Cachectin) as an Essential Mediator in Murine Cerebral Malaria," <i>Science</i> , 237:1210-1212 (1987).
AR10	AR10	Barbanti, E., et al., "A high-affinity neutralizing anti-human TNF-alpha monoclonal antibody that cross-reacts with human TNF-beta," <i>Abstracts</i> , March 6th-9th (1991).
AS10	AS10	Jones, E.Y., et al., "Structure of tumour necrosis factor," <i>Nature</i> , 338:225-228 (1989).
AT10	AT10	Clark, W. R., "Types of Antibody Reactions," In <i>The Experimental Foundations of Modern Immunology</i> , (NY: John Wiley & Sons, Inc.) 4th Ed., pp 143-155 (1991).
AU10	AU10	Beutler, B., et al., "Cachectin and tumour necrosis factor as two sides of the same biological coin," <i>Nature</i> , 320:584-588 (1986).
AV10	AV10	Folks, T. M., et al., "Tumor Necrosis factor α induces expression of human immunodeficiency virus in a chronically infected T-cell clone," <i>Proc. Natl. Acad. Sci. USA</i> , 86:2365-2358 (1989).
AX10	AX10	Hird, V., et al., "Immunotherapy with Monoclonal Antibodies," In <i>Genes and Cancer</i> (John Wiley & Sons, Ltd.) (1990).
AY10	AY10	Rhein, R., "Another sepsis drug down-Immunex' TNF receptor," <i>Biotechnology Newswatch</i> , Monday, October 4, 1993, pp. 1,3.
AZ10	AZ10	Boyle, P., et al., "A Novel Monoclonal Human IgM Autoantibody which Binds Recombinant Human and Mouse Tumor Necrosis Factor- α ," <i>Cellular Immunology</i> , 152:556-568 (1993).
AR11	AR11	Boyle, P., et al., "The B5 Monoclonal Human Autoantibody Binds to Cell Surface TNF α on Human Lymphoid Cells and Cell Lines and Appears to Recognize a Novel Epitope," <i>Cellular Immunology</i> , 152:569-581 (1993).
AS11	AS11	Sheehan, K.C.F., et al., "Generation And Characterization Of Hamster Monoclonal Antibodies That Neutralize Murine Tumor Necrosis Factors," <i>The Journal of Immunology</i> , 142(11):3884-3893 (1989).
		Jacob, C.O., et al., "Tumour necrosis factor- α in murine autoimmune 'lupus' nephritis," <i>Nature</i> , 331:356-358 (1988).
EXAMINER <i>Marin G. Gault</i>		DATE CONSIDERED 6/21/2004

Statement Under 37 CFR 1.97(e)

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- ☐ Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.
- ☒ Enclosed herewith is form PTO-1449:
- ☒ Copies of the cited references are enclosed.
- ☐ Copies of cited references are enclosed except those entered in prior applications, U.S. Application No. _____, to which priority under 35 U.S.C. 120 is claimed. The earlier applications contains copies of the cited references.
- ☐ The listed references were cited in the enclosed International Search Report in a counterpart foreign application.
- ☐ The "concise explanation" requirement (non-English references) for reference(s) [] under 37 CFR 1.98(a)(3) is satisfied by:
- ☐ the explanation provided on the attached sheet.
- ☐ the explanation provided in the Specification.
- ☐ submission of the enclosed International Search Report.
- ☐ the enclosed English language abstract.
- ☒ Applicant requests that the following pending applications be considered:

Examiner's
Initials

KAC

U.S. Patent Application No. 09/756,398, by Junming Le, Jan Vilcek, Peter Daddona, John Ghayeb, David M. Knight and Scott Siegel, filed January 8, 2001, Docket No.: 0975.1005-006

KAC

U.S. Patent Application No. 09/756,301, by Junming Le, Jan Vilcek, Peter Daddona, John Ghayeb, David M. Knight and Scott Siegel, filed January 8, 2001, Docket No.: 0975.1005-008

KAC

U.S. Patent Application No. 09/766,535, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed January 18, 2001, Docket No.: 0975.1005-010

U.S. Patent Application No. 09/927,703, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed August 10, 2001, Docket No.: 0975.1005-013

U.S. Patent Application No. 10/010,229, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed December 7, 2001 Docket No.: 0975.1005-014

U.S. Patent Application No. 10/043,450, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed January 10, 2002, Docket No.: 0975.1005-015

U.S. Patent Application No. 10/044,534, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed January 10, 2002, Docket No.: 0975.1005-016

U.S. Patent Application No. 10/043,432, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed January 10, 2002, Docket No.: 0975.1005-017

U.S. Patent Application No. 10/043,436, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed January 10, 2002, Docket No.: 0975.1005-018

U.S. Patent Application No. 10/176,460, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed June 20, 2002, Docket No.: 0975.1005-019

U.S. Patent Application No. 10/187,121, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed June 28, 2002, Docket No.: 0975.1005-020

U.S. Patent Application No. 10/186,559, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed June 28, 2002, Docket No.: 0975.1005-021

U.S. Patent Application No. 10/198,845, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed July 18, 2002, Docket No.: 0975.1005-022

U.S. Patent Application No. 10/200,795, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed July 22, 2002, Docket No.: 0975.1005-023

KAC
U.S. Patent Application No. 10/208,145, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed July 29, 2002, Docket No.: 0975.1005-024

Marin D. Camilla
Examiner

9/26/2002
Date

- ☒ [X] The specification for the above cited co-pending applications is identical to the present specification (09/897,724). Therefore, only a copy of the current claims for each application is enclosed. Copies of the specifications of the co-pending applications will be provided upon request.
- ☐ [] A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

- ☐ [] A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.
- ☐ [] Please charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is enclosed.
- ☒ [X] Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Deirdre E. Sanders

Deirdre E. Sanders

Registration No.: 42,122

Telephone: (978) 341-0036

Facsimile: (978) 341-0136

Concord, Massachusetts 01742-9133

Dated: September 13, 2002